Pre-Market Technical Scan on Biotech Equities -- Grifols, Advaxis, Nektar Therapeutics, and Spark Therapeutics

Wednesday, January 3, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 3, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on GRFS, ADXS, NKTR, and ONCE which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, January 02, 2018, US markets saw broad based gains with eight
out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,006.90, up 1.50%; the Dow Jones Industrial Average edged 0.42% higher, to finish at 24,824.01; and the S&P 500 closed at 2,695.81, up 0.83%. This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Grifols S.A. (NASDAQ: GRFS), Advaxis Inc. (NASDAQ: ADXS), Nektar Therapeutics (NASDAQ: NKTR), and Spark Therapeutics Inc. (NASDAQ: ONCE). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Grifols

On Tuesday, shares in Barcelona, Spain headquartered Grifols S.A. recorded a trading volume of 970,314 shares, which was above their three months average volume of 530.32 thousand shares. The stock ended the session 2.09% higher at $23.40. The Company's shares have gained 45.61% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 4.28% and 10.77%, respectively. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have a Relative Strength Index (RSI) of 66.87. Get the full research report on GRFS for free by clicking below at:

www.wallstequities.com/registration/?symbol=GRFS

Advaxis

Princeton, New Jersey-based Advaxis Inc.'s stock closed the day 9.15% higher at $3.10 with a total trading volume of 1.24 million shares, which was above their three months average volume of 773.62 thousand shares. The Company's shares have advanced 9.15% since the start of this year. The stock is trading below its 50-day moving average by 1.01%. Additionally, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 52.30.  Free research on ADXS can be accessed at:

www.wallstequities.com/registration/?symbol=ADXS

Nektar Therapeutics

Shares in San Francisco, California headquartered Nektar Therapeutics recorded a trading volume of 2.00 million shares. The stock ended yesterday's trading session 3.47% lower at $57.65. The Company's shares have advanced 132.74% over the previous three months and 369.85% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 32.71% and 119.32%, respectively. Furthermore, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 64.88. Sign up today for the free research report on NKTR at:

www.wallstequities.com/registration/?symbol=NKTR

Spark Therapeutics

Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock finished Tuesday's session 3.68% higher at $53.31 with a total trading volume of 630,682 shares. The Company's shares have advanced 5.40% in the past twelve months. The stock is trading below its 50-day moving average by 22.07%. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 40.70.

On December 14th, 2017, research firm Goldman downgraded the Company's stock rating from 'Buy' to 'Neutral' while revising its previous target price from $106 a share to $58 a share. Wall St. Equities' research coverage also includes the downloadable free report on ONCE at:

www.wallstequities.com/registration/?symbol=ONCE

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-biotech-equities----grifols-advaxis-nektar-therapeutics-and-spark-therapeutics-300576885.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store